17 February 2020
Esperite update the market
Esperite NV (Esperite, The Company) updates its shareholders on the current configuration and business of the company.
***
Cryo-Save Group N.V.
Secondary listing Euronext Paris starts 7 July 2014, name change to Esperite N.V scheduled for 2 July 2014
Zutphen, the Netherlands – 30 June 2014
Cryo-Save Group N.V.
La seconde cotation sur Euronext Paris débute le 7 juillet 2014, le changement de dénomination social en Esperite N.V. est fixé au 2 juillet 2014
Zutphen, Pays-Bas – le 30 juin 2014
Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international stem cell storage company and the largest family stem cell bank in Europe, announces that it has signed an asset sale and purchase agreement to acquire all assets that are exclusively related to the distribution and commercial activities of the umbilical cord blood and umbilical cord tissue cryopreservation business of Salveo Biotechnology S.A., Switzerland and its subsidiaries, effective as of 1 January 2014.
